每日经济新闻 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不 预示未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参 考，不构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险 等级相匹配的产品。基金有风险，投资需谨慎。 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 申万宏源证券指出，科创板深化改革细则增强了资本市场对科技创新和新质生产力发展的制度包容 性，科创成长层的设置彰显政策支持导向，未盈利企业上市通道开启，预期后续会有更多未盈利科创企 业申报IPO。改革对新股发行带来结构性影响，结合6月受理潮显效，预期25H2新股发行节奏小幅提 速，下半年或迎未盈利科创企业上市。中性情形下，25H2预测2亿元优配/非优配对象收益率为 2.79%/2.54%。预先审阅机制正式启动后，IPO审核效率将进一步提升 ...

打开热门网络平台，不时有"妇科医生"给男士T恤带货，"骨科医生"推销美容产品，"神经康复科"医生 侃侃而谈食用益生菌的好处；还有人穿上白大褂、伪造专家资质，堂而皇之地向用户推荐药品。这 些"假科普、真带货"的视频，在老年群体中十分受欢迎。 当前，随着公众健康意识增强，医疗科普领域热度不断提升。新华每日电讯记者调查发现，一些网络平 台上本应传递专业知识、守护大众健康的医疗科普，近来却在流量裹挟下"变了味"：从"耸人听闻"误导 受众，再到利用"擦边话题"博眼球，部分医疗从业者在平台上利用自身专业光环，以科普之名行"牟利 之实"。种种行为不仅消解了行业公信力，更置患者健康于风险之中。 明面科普，暗地里全是"生意" 一些平台对医疗从业者的身份审核漏洞，也助长了"造假引流"的气焰。很多账号并无认证信息，仅 凭"白大褂""手术服"等元素，以及与医疗相关的用户名便擦边带货。 "有的'网红医生'把医疗科普当作牟利工具，滥用专业权威为自己背书，假借科普名义违规导医导诊， 线上问诊，线下引流，直播带货……"7月4日，国家卫健委召开新闻发布会，新闻发言人胡强强指出当 前互联网健康科普存在的问题，再次将长期存在却未得到根治的医疗科普 ...

Core Insights - UnitedHealth Group Inc. (UNH) is facing challenges in the healthcare sector, particularly with its Medicare Advantage business under regulatory scrutiny and rising care costs, while its commercial insurance segment is providing stability [1][4] Group 1: Business Performance - As of March 31, 2025, UnitedHealthcare served 50.1 million people, marking a 1.9% year-over-year growth, primarily driven by self-funded commercial benefits [2] - The commercial segment, with over 30 million members, benefits from favorable pricing and a healthier risk pool compared to government plans, showing consistent growth [2][9] - Despite pulling back on full-year guidance due to ongoing pressures, the commercial division continues to act as a buffer against uncertainty in the broader economy [4] Group 2: Leadership and Strategy - Following the return of former CEO Stephen Hemsley in May 2025, the company is focusing on tightening controls and compliance in its Medicare operations while emphasizing growth in its commercial portfolio [3] Group 3: Competitive Landscape - Competitors like Molina Healthcare have warned about rising medical costs, leading to a reduction in their earnings guidance for 2025 [6] - Cigna has strategically sold off its Medicare-related businesses to focus on a commercial-heavy model, which has resulted in impressive first-quarter results driven by premium rate increases [7] Group 4: Valuation and Estimates - UnitedHealth's shares have decreased by 39.9% year-to-date, compared to a 32.3% decline in the industry [8] - The company trades at a forward price-to-earnings ratio of 12.85, above the industry average of 11.5, and has a Value Score of B [10] - The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is $21.85 per share, reflecting a 21% decline from the previous year [12]

Key Takeaways Ventas has outperformed the industry with an 11.6% stock gain in the past six months. VTR expects senior housing and outpatient NOI growth, fueled by aging demographics. Liquidity of $3.6B and accretive investments in research portfolio strengthen Ventas' growth outlook.Shares of Ventas (VTR) have gained 11.6% in the past six months compared with the industry’s 6% growth.This Chicago-based healthcare real estate investment trust (”REIT”) is well-poised to benefit from its diverse portfolio o ...

Core Viewpoint - Elevance Health, Inc. (ELV) is expected to report its second-quarter 2025 results on July 17, 2025, with earnings estimated at $9.20 per share and revenues of $48.13 billion, reflecting an 11.4% year-over-year increase in revenues [1][6]. Financial Estimates - The second-quarter earnings estimate has declined by 1.8% over the past 60 days, indicating a year-over-year decline of 9.1% in earnings, while the revenue estimate suggests an 11.4% year-over-year increase [2]. - For the full year 2025, the revenue estimate stands at $195 billion, representing an 11.3% year-over-year increase, and the EPS estimate is $34.40, implying a 4.1% year-over-year increase [3]. Earnings Performance - Elevance has beaten the consensus estimate in three of the last four quarters, with an average surprise of negative 1.2% [3]. - The current Earnings ESP is 0.00%, and the Zacks Rank is 3 (Hold), indicating uncertainty regarding an earnings beat this quarter [4]. Revenue Drivers - The consensus estimate for product revenues indicates an 11.1% growth from the previous year's $5.5 billion, while premiums are expected to increase by 11.9% year-over-year [5]. - Growth in CarelonRx and recent acquisitions in home health and pharmacy services are anticipated to support revenue growth [8]. Expense Considerations - Elevated expenses are expected due to significant investments in digital capabilities, with total expenses projected to rise nearly 11% year-over-year [9]. - The benefit expense ratio is estimated at 88.4, higher than the previous year's 86.3, which may impact profit margins [9]. Segment Performance - The Health Benefits segment's operating income is expected to decrease by 12.4% year-over-year, with declining Medicaid memberships affecting premium growth [10].

SAN FRANCISCO, July 14, 2025 (GLOBE NEWSWIRE) -- Healthcare giant Centene Corporation (NYSE: CNC), a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks to represent investors who purchased or acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchan ...

New Tier Adds EMR Integration, Team Reporting (IDT) and Custom Form Support — Enabling Scalable Deployment Across Entire Patient CensusDETROIT, July 14, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, today announced the launch of the new NurseMagic™ Enterprise Tier, built to meet the most urgent needs of mid- and large-scale post-acute healthcare providers. Developed in direct response to customer demand, NurseMagic™ Enterprise integrates advanc ...

Investment Rating - The report maintains a "Buy" rating for Asymchem, Kangji Medical, Weigao, Angelalign, and Hygeia, while Tigermed, WuXi XDC, WuXi Biologics, and Frontage are rated as "Neutral" [11][15][18][27][36]. Core Insights - The report highlights a recovery in the healthcare sector, particularly in the CDMO segment, with expectations for earnings resilience driven by new order growth and demand from both US and EU markets, as well as from Chinese biotech licensing [2][3]. - The Medtech sector is anticipated to see clearer recovery in the second half of 2025, supported by normalized hospital activity and new product contributions [3]. - The report emphasizes the importance of monitoring pricing competition and consumption recovery signals in the services sector, particularly in consumer-related categories [4]. Summary by Sections CRO/CDMO - Earnings are expected to remain resilient, especially for companies with exposure to late-stage development and manufacturing projects [2]. - Key investor focus areas include new order growth, client behavior shifts amid policy uncertainties, and pricing and margin recovery [2][13]. - EPS estimates have been revised upward by an average of 1.3% to 1.4% for 2025-2027, with target prices adjusted by an average of 4% [1]. Medtech - Recovery is expected to materialize more clearly in the second half of 2025, with key areas to watch including the pace of VBP rollout and surgical volume trends [3]. - Companies like Weigao and Kangji are ramping up new product launches and global expansions, despite some tariff-related uncertainties [3]. Services - Reimbursement control and DRG/DIP pressure are likely to persist, impacting pricing and volumes [4]. - The report notes a cautious outlook for M&A activity, with companies like Hygeia becoming more positive while others remain cautious [9]. Financial Estimates - The report provides detailed financial estimates for various companies, indicating expected sales growth and net income projections for FY25 and beyond [14][19]. - For instance, WuXi Apptec is projected to achieve a revenue growth of 10-15% for FY25, while Asymchem anticipates double-digit revenue growth alongside margin improvements [19]. Target Price Changes - Target prices for several companies have been adjusted, with Asymchem's target price increased to HK$85.5, reflecting a 13% change [11][15]. - WuXi Biologics' target price is set at HK$25.6, based on a 12-month forward P/E of 22x [15][31]. Backlog and Order Trajectory - The report includes a detailed analysis of backlog and new order trajectories for key players in the CRO/CDMO space, indicating significant year-on-year growth in sales and backlog for companies like WuXi Apptec and WuXi Biologics [17].

Core Viewpoint - The S&P 500's dividend yield is nearing record lows at approximately 1.2%, yet there are several high-quality companies offering dividends with yields of 5% or more, providing opportunities for passive income seekers [1]. Group 1: High-Yield Dividend Stocks - Realty Income has a dividend yield above 5.5%, supported by a diversified real estate portfolio and a strong financial profile, with a record of 661 consecutive monthly dividends and 131 increases since its IPO in 1994 [4][6]. - Clearway Energy's dividend yield is just below 5.5%, with stable cash flow generated from long-term power purchase agreements, and plans to grow cash available for dividends from $2.08 per share this year to over $2.50 by 2027 [7][8]. - Healthpeak Properties offers a yield over 6.5%, with a high-quality portfolio of healthcare properties and a strong financial profile, including $500 million to $1 billion in capacity for additional investments [9][10]. - Oneok's dividend yield exceeds 5%, with 90% of earnings from fee-based sources, aiming for a 3% to 4% annual increase in dividends supported by acquisition synergies and expansion projects [11][12]. - Verizon has a dividend yield approaching 6.5%, generating $19.8 billion in free cash flow last year, which comfortably covered its $11.2 billion in dividend payments, allowing for continued dividend increases [13][14]. Group 2: Investment Rationale - Realty Income, Clearway Energy, Healthpeak Properties, Oneok, and Verizon all provide dividends above 5%, backed by recurring cash flow and strong balance sheets, making them solid choices for passive income investments [15].

Group 1 - The Fidelity MSCI Health Care Index ETF (NYSEARCA: FHLC) is a passive ETF that invests in the healthcare industry and its performance aligns with industry peers [1] - The article emphasizes the importance of examining small details when analyzing the ETF's performance [1] Group 2 - The author has a background in finance, with expertise in corporate finance, M&A, and investment analysis, particularly in real estate, renewable energy, and equity markets [1] - The author aims to share insights and analysis on companies of interest to a global audience, promoting informed decision-making [1]